Skip to main content

Market Overview

Recap: Amarin Q2 Earnings


Shares of Amarin Corp (NASDAQ:AMRN) rose 2.2% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share were up 200.00% over the past year to $0.01, which beat the estimate of ($0.07).

Revenue of $135,317,000 higher by 34.25% from the same period last year, which missed the estimate of $149,480,000.


Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: Aug 04, 2020

Time: 07:30 AM

ET Webcast URL:

Price Action

Company's 52-week high was at $26.12

Company's 52-week low was at $3.95

Price action over last quarter: down 5.72%

Company Overview

Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular health. Its products include Vascepa.


Related Articles (AMRN)

View Comments and Join the Discussion!

Posted-In: Earnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at